Psoriasis IL-23 Biologic Maintains Efficacy in 2-Year Trial

]]>(MedPage Today) -- The interleukin (IL)-23 inhibitor biologic risankizumab (Skyrizi) showed superior efficacy to placebo in treating moderate to severe plaque psoriasis, according to the last in a series of phase III trials for the drug.After...